EDSA Edesa Biotech: Forward P/S Multiple
Edesa Biotech, Inc. (EDSA) develops immune therapies to combat respiratory pathologies through government partnerships. The absence of sales and rising monitoring costs during late-stage trials drive the forward price-to-sales ratio, which currently stands at . The business's financial stability relies entirely on the results of clinical trials for anti-inflammatory drugs.
Analytical breakdowns for Edesa Biotech, Inc.
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt and liquidity data:
Debt to Equity Edesa Biotech, Inc.|EDSA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Edesa Biotech, Inc.|EDSA - Company Aggregate Debts|Debt to Book Value Edesa Biotech Corp|EDSA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Edesa Biotech|Quick Ratio edesabiotech.com
- financial results and valuation multiples details:
EDSA - Net Financial Result|Expected Profit Edesa Biotech, Inc.|EDSA - Market Cap to Earnings|Projected Price to Earnings Edesa|EDSA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Edesa Biotech Corp|EDSA - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Edesa Biotech|EDSA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth edesabiotech.com|EDSA - Earnings per share increase in current year|Expected earnings per share growth for next year Edesa Biotech, Inc.
- sales and revenue indicators:
Fundamental company analysis:Edesa Biotech (EDSA)
The specific nature of Edesa Biotech, Inc. (EDSA) and its concentration on a limited number of respiratory therapy drugs makes the business extremely sensitive to clinical trial results. An analysis of the forward P/S ratio allows for a comparison of current market capitalization against expected revenue, identifying either unjustified overvaluation or growth potential, which is critical given the company's high dependence on binary development risks.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio ADMA Corp|PTGX: Forward P/S Multiple|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grifols SA GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Market Cap to Expected Sales Ratio Celldex Corp|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Forward P/S Multiple biocryst.com BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|PHVS: Forward P/S Multiple|ABCL (AbCellera Corp) - Price-to-Projected Revenue Ratio|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR - Market Cap to Future Revenue Ratio|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ZBIO (Zenas Corp)|Immunome, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio gossamerbio.com|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna, Inc.|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|SVRA: Forward Price to Sales|Forward Price-to-Revenue Multiple RIGL (Rigel Pharmaceuticals)|ANAB (anaptysbio.com) - Forward Price to Sales|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|Market Cap to Expected Sales Ratio enGene Holdings Inc (ENGN)|RAPT - Price-to-Projected Revenue Ratio|JBIO (Aerovate Therapeutics Inc) - Market Cap to Projected Revenue|ACRS: Forward P/S Multiple|Forward Price-to-Revenue Multiple kyvernatx.com|Forward Price-to-Revenue Multiple TLSA|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VTYX|THTX - Market Cap to Future Revenue Ratio|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|ELDN: Market Cap to Projected Revenue|AGEN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Climb Bio Inc. CLYM|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Adagene Inc|Ikena Oncology, Inc. - Future Price to Revenue|Forward P/S Multiple STTK|EQ (equilliumbio.com) - Forward Price to Sales|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA - Price-to-Projected Revenue Ratio|Forward Price to Sales IFRX (InflaRx N.V.)|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adicet Bio, Inc.|CELU (Celularity Inc) - Forward P/S Multiple|Forward P/S Multiple INmune Bio Corporation|Forward Price-to-Revenue Multiple BRNS (Barinthus Biotherapeutics)|KZR (kezarlifesciences.com) - Forward Price to Sales|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Market Cap to Expected Sales Ratio Akari Therapeutics PLC (AKTX)|ENLV - Price-to-Projected Revenue Ratio|Q32 Bio Inc. (QTTB) - Forward Price-to-Revenue Multiple|GeoVax Labs, Inc. (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Forward Price-to-Revenue Multiple CARM|Forward P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Projected Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Market Cap to Future Revenue Ratio|Aditxt Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GRI Bio Inc|XRTX: Forward P/S Multiple|Market Cap to Projected Revenue HIND|REVB (Revelation Biosciences) - Forward P/S Multiple|Market Cap to Future Revenue Ratio indaptusrx.com INDP|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|Market Cap to Expected Sales Ratio calcimedica.com|Forward P/S Multiple AFMD (Affimed N.V.)|Forward P/S Multiple Allakos Inc ALLK|HOOK: Forward Price-to-Revenue Multiple|Forward Price to Sales IGMS (IGM Biosciences, Inc.)|ITOS: Forward P/S Multiple|OCEA (Ocean Biomedical Inc) - Price-to-Projected Revenue Ratio|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Third Harmonic Bio Inc (THRD) - Market Cap to Expected Sales Ratio
